Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant by Sophie Marbaix, Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, Pascal Van Bleyenbergh, Keliane Liberman, Dimitri Dehenau

“…BackgroundNirmatrelvir-ritonavir is an oral treatment for SARS-CoV-2 infection in patients who are at high risk of developing severe COVID-19 disease. …”
Get full text

Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study by Renxian Xie, Renxian Xie, Hongxin Huang, Hongxin Huang, Qingxin Cai, Jiayang Lu, Tong Chen, Tong Chen, Keyan Xie, Jianzhou Chen, Chuangzhen Chen

“…This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated arc therapy (HS VMAT) in patients with World Health Organization (WHO) grade II glioma.MethodsHS VMAT plans and non-hippocampus-sparing volumetric-modulated arc therapy (NHS VMAT) plans were generated using a computed tomography (CT) dataset of 10 patients who underwent postoperative radiotherapy. …”
Get full text

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors by Yen-Wen Chen, Helene Hardy, Christopher D. Pericone, Wing Chow

“…**Background:** Studies have shown an increase in weight among people living with human immunodeficiency virus (PLWH) who have also initiated integrase strand transfer inhibitors (INSTI). …”
Get full text

Emergent patterns in global health diplomacy: a network analysis of the resolutions adopted by the World Health Assembly from 1948 to 2022 by Kelley Lee, Didier Wernli, Nicolas Levrat, Bastien Chopard, Jean-Luc Falcone, Stephan Davidshofer

“…This article uses a computer-assisted methodology to better understand governance systems as a network of norms. All World Health Assembly (WHA) resolutions that were available from 1948 to 2022 were collected from the WHO Institutional Repository for Information Sharing (IRIS) database. …”
Get full text

Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China by Yiqing Zhu, Yihan Wang, Jinghui Wang, Yafei Wang, Li Sun, Shiheng Cui, Jing Li, Yu Guo

Get full text

“A one-stop shop”: Real-world use and app-users' experiences of a psychoeducational smartphone app for adults with ADHD by Christina Seery, Rachel Hannah Cochrane, Martha Mulcahy, Ken Kilbride, Margo Wrigley, Jessica Bramham

“…The present study aimed to investigate acceptability and user engagement of the Adult ADHD App by auditing real-world use data and gaining qualitative feedback from app users. …”
Get full text

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence by Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Get full text

Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013–2019 by Przemysław Leszek, Daniel Waś, Kinga Bartolik, Kladiusz Witczak, Andrzej Kleinork, Bohdan Maruszewski, Katarzyna Brukało, Paulina Rolska‐Wójcik, Małgorzata Celińska‐Spodar, Tomasz Hryniewiecki, Marta Załęska‐Kocięcka

Get full text

Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments by Ning Ning, Sunandana Chandra, Andriy Moshyk, Divya Patel, Isabella C Glitza Oliva, Jennell Palaia, Leon A Sakkal, Natalia Han, Shardul Odak, Jordana K Schmier

“…Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared between treatments in a univariate Cox proportional hazards model.Results In total, 472 patients with MBM who received first-line nivolumab plus ipilimumab (n=246), anti-PD-1 monotherapy (n=112) or BRAF/MEK inhibitors (n=114) were identified. …”
Get full text

Patterns and factors associated with healthcare utilisation in Cambodia: a cross-sectional study based on the World Health Survey Plus 2023 by Kerstin Klipstein-Grobusch, Por Ir, Paul Kowal, Nawi Ng, Srean Chhim, Chhorvann Chhea, Chamnab Ngor, Sereyraksmey Long, Poppy Walton, Khin Thiri Maung, Grace Marie Ku, Heng Sopheab

Get full text

Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients by Yu-Xuan Song, Guang-Jun Song, Hui Ma, Bo Feng, Yan-Di Xie

“…Background/Aims: This study assessed the long-term efficacy and safety of tenofovir alafenamide (TAF) in real-world settings. Methods: Patients who were candidates for TAF treatment and were followed up at 12-week intervals over 192 weeks were enrolled in this study. …”
Get full text

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study by Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu

Get full text

Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital by Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeon Park, Gheeyoung Choe, Jee Hyun Kim, Jin-Haeng Chung

“…Of 32 patients with measurable lesions who received NGS-based therapy, 12 (37.5%) achieved a partial response, and 11 (34.4%) achieved stable disease. …”
Get full text

Erratum to ‘Should post-operative stereotactic radiosurgery be the standard of care in Craniopharyngioma patients?’ [World Neurosurgery: X (22C) (2024) 100327] by Saurabh Gupta, Deepak Agrawal, Shweta Kedia, Shashank Sharad Kale

Get full text

Population characteristics, prescription patterns and glycemic control of users of flash glucose monitoring systems in Brazil: a real-world evidence study by Karla Santo, Josué Nieri, Karine Risério, Karla F. S. Melo

“…Conclusion This is the first and largest real-world evidence study that describe and compare fCGM and BGM in users of a digital health patient support platform in Brazil. fCGM users were significantly different from those who perform BGM, in terms of population characteristics and treatment patterns. …”
Get full text

Caesarean Section Rates and Activity-Based Funding in Northern Norway: A Model-Based Study Using the World Health Organization’s Recommendation by Jan Norum, Tove Elisabeth Svee

“…Caesarean section (CS) rates vary significantly worldwide. The World Health Organization (WHO) has recommended a maximum CS rate of 15%. …”
Get full text

Osmanlı Devleti’nde Zorunlu Askerliğe Direniş: ‘Muînsiz’ Efrad Problemi by Rıza ÖZBÖLÜK

“…Since this method was widely applied, the compulsory military system became inextricable and finally, the exemption categories were abolished just before the World War One. …”
Get full text

Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) by Md Faruque Pathan, Nazma Akter, Marufa Mustari, M. Saifuddin, Mirza Sharifuzzaman, Mohammad Motiur Rahman, Mohammed Ripon, S. M. Mohiuddin, A. B. M. Kamrul-Hasan, Mohammad Abdul Hannan, Muhammad Shah Alam, Samira Mahjabeen, Faria Afsana, Muhammed Abu Bakar, Tahniyah Haq, Afsar Ahammed, Samir Kumar Talukder, Sourav Sarkar, Shahjada Selim

Get full text

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study by Nayana Hitesh Patel, Niket H. Patel, Molina Niket Patel, Harsha K. Bhadarka, Kairavi Sunilkumar Vyas

“…Background: Biosimilar drugs have broadened the treatment options in assisted reproductive technology (ART). Real-world data comparing clinical outcomes of originator follitropin alfa (Gonal-f®) with its biosimilars are required to enrich the body of evidence for clinical decision-making on choice of drug. …”
Get full text